<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723512</url>
  </required_header>
  <id_info>
    <org_study_id>Subproject MRI ACH471-205</org_study_id>
    <nct_id>NCT03723512</nct_id>
  </id_info>
  <brief_title>Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study</brief_title>
  <official_title>Sub-project of the Clinical Protocol ACH471-205 &quot;An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional and quantitative renal magnetic resonance imaging (MRI) has seen a number of
      recent advances, and techniques are now available that can generate quantitative imaging
      biomarkers with the potential to improve the management of kidney disease.

      However, there are knowledge gaps that must be addressed before renal MRI methods could be
      more widely adopted in clinical research and ultimately be transferred to clinical practice,
      including the biological basis of different MRI biomarkers, and how the application of these
      biomarkers will improve patient care.

      Among renal MRI techniques, renal diffusion weighted MRI (DWI) has been increasingly used in
      the last decade, showing high potential as a surrogate and monitoring biomarker for
      interstitial fibrosis in chronic kidney disease (CKD), as well as a surrogate biomarker for
      the inflammation in acute kidney diseases that may impact patient selection for renal biopsy
      in acute graft rejection.

      Within the ready-to-start ACH471-205 clinical trial, an Open-Label Phase 2 Proof-of-Concept
      Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative
      Glomerulonephritis (IC-MPGN) treated with ACH-0144471, aimed at evaluating the efficacy of 12
      months of oral ACH-0144471 in patients with C3G or IC-MPGN, patients will undergo baseline
      and 12-month follow-up renal biopsies, and renal function will be assessed over time by
      estimated or measured (when available) glomerular filtration rate (GFR). Adding
      multi-parametric NCE-MRI to the examinations under the ACH471-205 study protocol will give
      the opportunity to elucidate, in a well-defined cohort of patients, the potential of NCE-MRI
      as biomarker of renal microstructure and functional change.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median diffusivity (D) in the kidney, renal cortex and medulla.</measure>
    <time_frame>At baseline (prior to baseline biopsy).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median diffusivity (D) in the kidney, renal cortex and medulla.</measure>
    <time_frame>At 12 months (prior to follow-up biopsy).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal artery blood flow and renal plasma flow.</measure>
    <time_frame>At baseline (prior to baseline biopsy).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal artery blood flow and renal plasma flow.</measure>
    <time_frame>At 12 months (prior to follow-up biopsy).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in median diffusivity in the kidney, renal cortex and medulla after 12-month treatment with ACH-0144471.</measure>
    <time_frame>At 12 months follow-up.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal artery blood flow and renal plasma flow after 12-month treatment with ACH-0144471.</measure>
    <time_frame>At 12 months follow-up.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>C3 Glomerulonephritis</condition>
  <condition>C3 Glomerulopathy</condition>
  <condition>Immune Complex Membranoproliferative Glomerulonephritis</condition>
  <condition>IC-MPGN</condition>
  <condition>Dense Deposit Disease</condition>
  <arm_group>
    <arm_group_label>Whole group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non contrast-enhanced magnetic resonance imaging</intervention_name>
    <description>Non contrast-enhanced magnetic resonance imaging</description>
    <arm_group_label>Whole group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of C3G or IC-MPGN;

          -  Patients enrolled in the ACH471-205 study at the Bergamo center;

          -  No contraindications to perform MRI.

        Exclusion Criteria:

        - Ferro-magnetic prosthesis, aneurysm clips, severe claustrophobia or other
        contraindications or exclusions interfering with the MRI assessment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò</name>
      <address>
        <city>Ranica</city>
        <state>BG</state>
        <zip>24020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Selby NM, Blankestijn PJ, Boor P, Combe C, Eckardt KU, Eikefjord E, Garcia-Fernandez N, Golay X, Gordon I, Grenier N, Hockings PD, Jensen JD, Joles JA, Kalra PA, Krämer BK, Mark PB, Mendichovszky IA, Nikolic O, Odudu A, Ong ACM, Ortiz A, Pruijm M, Remuzzi G, Rørvik J, de Seigneux S, Simms RJ, Slatinska J, Summers P, Taal MW, Thoeny HC, Vallée JP, Wolf M, Caroli A, Sourbron S. Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrol Dial Transplant. 2018 Sep 1;33(suppl_2):ii4-ii14. doi: 10.1093/ndt/gfy152.</citation>
    <PMID>30137584</PMID>
  </reference>
  <reference>
    <citation>Caroli A, Schneider M, Friedli I, Ljimani A, De Seigneux S, Boor P, Gullapudi L, Kazmi I, Mendichovszky IA, Notohamiprodjo M, Selby NM, Thoeny HC, Grenier N, Vallée JP. Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper. Nephrol Dial Transplant. 2018 Sep 1;33(suppl_2):ii29-ii40. doi: 10.1093/ndt/gfy163.</citation>
    <PMID>30137580</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>July 1, 2019</last_update_submitted>
  <last_update_submitted_qc>July 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-contrast enhanced MRI</keyword>
  <keyword>Diffusivity</keyword>
  <keyword>Renal microstructure</keyword>
  <keyword>Renal function</keyword>
  <keyword>C3G</keyword>
  <keyword>IC-MPGN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranoproliferative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

